SAN DIEGO--(BUSINESS WIRE)--CeleCor Therapeutics, Inc. today announced preliminary positive results in the company’s ongoing phase 1 clinical study with RUC-4, a novel subcutaneous platelet GPIIb/IIIa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback